公开(公告)号：US20210261964A1

公开(公告)日：2021-08-26

申请号：US17260418

申请日：2019-07-18

申请人： THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY ,  OSAKA UNIVERSITY ,  TEIKYO UNIVERSITY

发明人： Taiki AOSHI ,  Shohei KOYAMA ,  Ryo SUZUKI

IPC分类号： C12N15/117 ,  A61K9/107 ,  A61K31/7088 ,  A61K47/28 ,  A61K47/24 ,  A61K47/54 ,  A61P35/00

摘要： An object is to provide a technology that can stably exhibit the effects of A-type CpG oligodeoxynucleotides. The object can be achieved by a lipid particle comprising an A-type CpG oligodeoxynucleotide.

公开(公告)号：US20180223326A1

公开(公告)日：2018-08-09

申请号：US15579953

申请日：2016-06-17

申请人： The Research Foundation For Microbial Diseases Of Osaka University ,  Osaka University

发明人： Yukihiro Akeda ,  Hiroshi Miyatake ,  Zhenyu Piao ,  Yuka Koizumi

IPC分类号： C12Q1/18

CPC分类号： C12Q1/18 ,  C07K16/12 ,  C12N1/20 ,  G01N2333/3156

摘要： The present invention relates to a measurement method for complement-dependent bactericidal activity against Streptococcus pneumoniae, and provides a measurement method capable of measuring complement-dependent bactericidal activity against Streptococcus pneumoniae of any capsular serotype. Complement-dependent bactericidal activity against Streptococcus pneumoniae is measured using capsule-deficient Streptococcus pneumoniae, that is, non-encapsulated or substantially non-encapsulated, or transparent Streptococcus pneumoniae. The measurement of the complement-dependent bactericidal activity against Streptococcus pneumoniae of any capsular serotype is enabled.

公开(公告)号：US09181328B2

公开(公告)日：2015-11-10

申请号：US14375675

申请日：2013-01-31

申请人： OSAKA UNIVERSITY ,  THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY ,  MEDICAL AND BIOLOGICAL LABORATORIES CO., LTD. ,  DEPARTMENT OF MEDICAL SCIENCES

发明人： Mayo Yasugi ,  Motoki Kuhara ,  Jotika Boon-Long ,  Kazuhito Fujiyama ,  Ritsuko Koketsu ,  Kazuyoshi Ikuta

IPC分类号： C07K16/10 ,  G01N33/569 ,  A61K39/00

CPC分类号： C07K16/1018 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/54 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/56983 ,  G01N2333/11

摘要： Materials and methods are provided for treating influenza B infections in humans. Anti-human influenza virus monoclonal antibodies and antigen-binding fragments thereof having a neutralization activity against a human influenza B virus are provided. Methods for producing anti-human influenza B virus monoclonal antibodies are also provided. The antibodies and antigen-binding fragments thereof can be effective against a wide range of influenza B viral strains. Methods of inhibiting or treating a human influenza B infection are provided. The anti-influenza B therapeutics can also be used to manufacture medicaments effective against influenza B infections, to detect human influenza B in a human subject, for use in pharmaceutical compositions, and for use in kits for at least one of the prevention, the treatment, and the detection of human influenza B in a human subject.

摘要翻译： 提供了用于治疗人类B型流感病毒的材料和方法。 提供了抗人流感病毒单克隆抗体及其对人类B型流感病毒具有中和活性的抗原结合片段。 还提供了产生抗人B型流感病毒单克隆抗体的方法。 抗体及其抗原结合片段对于广泛的乙型流感病毒株是有效的。 提供了抑制或治疗人流感B感染的方法。 抗乙型流感病毒治疗剂也可用于制造有效抗B型流感病毒的药物，以检测人类受试者中的人类流感B，用于药物组合物，并用于至少一种预防，治疗 ，以及人类受试者中人类乙型流感的检测。

公开(公告)号：US20140377262A1

公开(公告)日：2014-12-25

申请号：US14375675

申请日：2013-01-31

申请人： OSAKA UNIVERSITY ,  THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY ,  MEDICAL AND BIOLOGICAL LABORATORIES CO., LTD. ,  DEPARTMENT OF MEDICAL SCIENCES

发明人： Mayo Yasugi ,  Motoki Kuhara ,  Jotika Boon-Long ,  Kazuhito Fujiyama ,  Ritsuko Koketsu ,  Kazuyoshi Ikuta

IPC分类号： C07K16/10 ,  G01N33/569

CPC分类号： C07K16/1018 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/54 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/56983 ,  G01N2333/11

摘要： Materials and methods are provided for treating influenza B infections in humans. Anti-human influenza virus monoclonal antibodies and antigen-binding fragments thereof having a neutralization activity against a human influenza B virus are provided. Methods for producing anti-human influenza B virus monoclonal antibodies are also provided. The antibodies and antigen-binding fragments thereof can be effective against a wide range of influenza B viral strains. Methods of inhibiting or treating a human influenza B infection are provided. The anti-influenza B therapeutics can also be used to manufacture medicaments effective against influenza B infections, to detect human influenza B in a human subject, for use in pharmaceutical compositions, and for use in kits for at least one of the prevention, the treatment, and the detection of human influenza B in a human subject.

摘要翻译： 提供了用于治疗人类B型流感病毒的材料和方法。 提供了抗人流感病毒单克隆抗体及其对人类B型流感病毒具有中和活性的抗原结合片段。 还提供了产生抗人B型流感病毒单克隆抗体的方法。 抗体及其抗原结合片段对于广泛的乙型流感病毒株是有效的。 提供了抑制或治疗人流感B感染的方法。 抗乙型流感病毒治疗剂也可用于制造有效抗B型流感病毒的药物，以检测人类受试者中的人类流感B，用于药物组合物，并用于至少一种预防，治疗 ，以及人类受试者中人类乙型流感的检测。

公开(公告)号：US09493550B2

公开(公告)日：2016-11-15

申请号：US14505515

申请日：2014-10-03

申请人： Osaka University ,  The Research Foundation for Microbial Diseases of Osaka University

发明人： Kazuyoshi Ikuta ,  Ritsuko Koketsu ,  Yoshinobu Okuno ,  Mikihiro Yunoki ,  Shoji Ideno ,  Masatoshi Oshita ,  Motoki Kuhara ,  Masatoshi Momota

IPC分类号： C07K16/10 ,  A61K39/00

CPC分类号： C07K16/1018 ,  A61K2039/505 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/76

摘要： Provided is a human antibody having a neutralization activity against a human influenza virus. More specifically, provided is a human antibody which recognizes a highly conserved region in a human influenza A virus subtype H3N2 or a human influenza B virus and has a neutralization activity against the virus. The human antibody is a human anti-human influenza virus antibody, which has a neutralization activity against a human influenza A virus subtype H3N2 and binds to a hemagglutinin HA1 region of the human influenza A virus subtype H3N2, or which has a neutralization activity against a human influenza B virus, and includes, as a base sequence of a DNA encoding a variable region of the antibody, a sequence set forth in any one of SEQ ID NOS: 5 to 12.

公开(公告)号：US20230302040A1

公开(公告)日：2023-09-28

申请号：US18143370

申请日：2023-05-04

申请人： OSAKA UNIVERSITY ,  NIPPON ZOKI PHARMACEUTICAL CO., LTD.

发明人： Hiroyuki TANAKA ,  Hideki YOSHIKAWA ,  Hideki MOCHIZUKI ,  Tsuyoshi MURASE ,  Tsutomu SASAKI ,  Kousuke BABA ,  Toru IWAHASHI ,  Mitsuru NAIKI

IPC分类号： A61K31/714 ,  A61P25/28 ,  A61K9/00

CPC分类号： A61K31/714 ,  A61P25/28 ,  A61K9/0019

摘要： An object is to provide a drug which is useful in treating a nervous system disease. A drug containing vitamin B12 as an active ingredient according to the present invention has an M2 macrophage/microglia induction promoting effect, an M1 macrophage/microglia induction inhibiting effect, a nerve regeneration promoting effect, and the like and is very useful as a therapeutic agent for a nervous system disease, and particularly useful as a therapeutic agent for a central nervous system disease such as cerebral infarction, dementia, or spinal cord injury.

公开(公告)号：US20140086927A1

公开(公告)日：2014-03-27

申请号：US14035495

申请日：2013-09-24

申请人： Fujita Health University ,  The Research Foundation for Microbial Diseases of Osaka University ,  Osaka University

发明人： Yoshikazu Kurosawa ,  Yoshitaka Iba ,  Nobuko Ohshima ,  Shigeyuki Yokoyama ,  Mikako Shirouzu ,  Yoshifumi Fujii ,  Tomomi Sumida ,  Kazuyoshi Ikuta ,  Shota Nakamura ,  Norihito Kawashita ,  Mitsuhiro Nishimura ,  Akifumi Yamashita ,  Yoshinobu Okuno ,  Ritsuko Kubota-Koketsu ,  Masahiro Okubo

IPC分类号： C07K16/10 ,  G01N33/569

CPC分类号： C07K16/1018 ,  C07K2299/00 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/76 ,  G01N33/56983 ,  G01N2333/11 ,  G16B15/00 ,  G16C20/50

摘要： Antibodies (Abs) play roles in protection against influenza. Neutralizing Abs either inhibit the binding of hemagglutinin (HA) to cellular receptors or prevent the conformational change of HA induced by low pH. The former Ab binds to the regions near the sialic acid-binding pocket on the globular head formed by HA1 and generally shows narrow strain specificity. The latter Ab binds to the stem region formed mainly by HA2 and shows broad strain specificity. We isolated a broadly neutralizing Ab against H3N2 viruses. X-ray analysis of the HA/Ab complex indicated that the Ab binds to the valley formed by two neighboring HA monomers at the side of the globular head. The Ab shows neutralizing activity by preventing the conformational change of HA induced at low pH.

摘要翻译： 抗体（Abs）在防止流行性感冒方面发挥作用。 中和抗体可抑制血细胞凝集素（HA）与细胞受体的结合，或阻止由低pH引起的HA的构象变化。 前者Ab与HA1形成的球形头上唾液酸结合口附近的区域结合，通常表现出狭窄的应变特异性。 后者Ab结合主要由HA2形成的茎区，并显示出广泛的应变特异性。 我们分离出一种广泛中和的Ab针对H3N2病毒。 HA / Ab复合物的X射线分析表明，Ab与球状头部侧面的两个相邻的HA单体形成的谷结合。 Ab通过防止在低pH下诱导的HA的构象变化来显示中和活性。

公开(公告)号：US08975378B2

公开(公告)日：2015-03-10

申请号：US13141998

申请日：2009-12-24

申请人： Kazuyoshi Ikuta ,  Ritsuko Koketsu ,  Yoshinobu Okuno ,  Mikihiro Yunoki ,  Shoji Ideno ,  Masatoshi Oshita ,  Motoki Kuhara ,  Masatoshi Momota

发明人： Kazuyoshi Ikuta ,  Ritsuko Koketsu ,  Yoshinobu Okuno ,  Mikihiro Yunoki ,  Shoji Ideno ,  Masatoshi Oshita ,  Motoki Kuhara ,  Masatoshi Momota

IPC分类号： C07K16/10 ,  C12N15/13 ,  A61K39/00

CPC分类号： C07K16/1018 ,  A61K2039/505 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/76

摘要： Provided is a human antibody having a neutralization activity against a human influenza virus. More specifically, provided is a human antibody which recognizes a highly conserved region in a human influenza A virus subtype H3N2 or a human influenza B virus and has a neutralization activity against the virus. The human antibody is a human anti-human influenza virus antibody, which has a neutralization activity against a human influenza A virus subtype H3N2 and binds to a hemagglutinin HA1 region of the human influenza A virus subtype H3N2, or which has a neutralization activity against a human influenza B virus, and includes, as a base sequence of a DNA encoding a variable region of the antibody, a sequence set forth in any one of SEQ ID NOS: 5 to 12.

摘要翻译： 本发明提供对人流感病毒具有中和活性的人抗体。 更具体地，提供了识别人流感A型病毒亚型H3N2或人类流感B型病毒中的高度保守区域并具有针对病毒的中和活性的人抗体。 人抗体是人抗流感病毒抗体，其对人甲型流感病毒亚型H3N2具有中和活性，并与人甲型流感病毒亚型H3N2的血凝素HA1区域结合，或者具有中和活性 人流感B病毒，并且作为编码抗体可变区的DNA的碱基序列，包含SEQ ID NO：5〜12中任一项所述的序列。

公开(公告)号：US12121356B2

公开(公告)日：2024-10-22

申请号：US17052513

申请日：2019-03-26

申请人： Osaka University

发明人： Tsuyoshi Sekitani ,  Shusuke Yoshimoto

IPC分类号： A61B5/257 ,  A61B5/00 ,  A61B5/25 ,  A61B5/282

CPC分类号： A61B5/257 ,  A61B5/282 ,  A61B5/683

摘要： An electrode sheet is provided which can be flexibly adapted to the position where a signal is acquired. This electrode sheet 1, which is attached to a living body M and acquires a biological signal, is provided with a sheet-form biological signal acquisition unit 10 which is attached to a living body part where a biological signal is acquired, and a reference potential acquisition unit 20 which extends from the living body signal acquisition unit and which is attached to a living body part where a reference potential is acquired, wherein the reference potential acquisition unit 20 is provided with multiple electrodes 23 which are arranged at a prescribed interval along the direction of extension and each of which can attach to the living body part where the reference potential is acquired.

公开(公告)号：US20240335480A1

公开(公告)日：2024-10-10

申请号：US18579100

申请日：2022-07-14

申请人： Astellas Pharma Inc. ,  OSAKA UNIVERSITY ,  National Center for Child Health and Development

发明人： Kenichiro SHIMATANI ,  Hiromu SATO ,  Masao SASAI ,  Yoshiki SAWA ,  Atsuhiro SAITO ,  Shigeru MIYAGAWA

IPC分类号： A61K35/545 ,  A61K35/44 ,  C12N5/071

CPC分类号： A61K35/545 ,  A61K35/44 ,  C12N5/069 ,  C12N2506/02 ,  C12N2513/00

摘要： An object of the present invention is to provide a pericyte-like cell having high angiogenic potential with a higher cell proliferation ability than a primary pericyte available in the past and high VEGF expression, and a method for producing the same. Provided are a method for producing a VEGF-highly expressing pericyte-like cell, the method including selecting a CD56(−) pericyte-like cell from a population including a pericyte-like cell obtained by inducing differentiation of a pluripotent stem cell; and a VEGF-highly expressing pericyte-like cell produced by the production method.